Shree Ganesh Remedies Q2 FY27 Revenue Down 23% YoY to ₹23.29 Cr

Shree Ganesh Remedies Limited announced its financial results for the second quarter and half year ended September 30, 2026. Revenue for Q2FY27 stood at ₹23.29 crore, a decrease of 23% year-on-year, with EBITDA at ₹3.94 crore (-59% YoY) and PAT at ₹1.63 crore (-67% YoY). For the half year ended September 30, 2026, revenue was ₹37.65 crore (-32% YoY), EBITDA ₹7.29 crore (-57% YoY), and PAT ₹2.75 crore (-67% YoY). The company cited subdued demand from Europe and a difficult operating environment as reasons for the challenging performance, but noted an improved Q2 performance driven by the pharmaceutical intermediates business and domestic market focus. New pharmaceutical intermediates for anti-diabetic and cardiovascular applications have been launched domestically and are planned for export. The company also reported progress in its CRAMS business and specialty chemicals projects, with commercial supplies expected from Q1FY28.